Lly stock forecast 2025 incorporates currency fluctuation

LLY stock forecast 2025 incorporates currency fluctuation impacts, with USD strength possibly trimming overseas revenue growth by 2%-3%. Hedged portfolios mitigate FX risks to protect core earnings. To make our list of Goldman Sachs’ top growth investment stocks, we used the bank’s recent list of stocks and picked out those with a growth investment ratio of 70% or higher. This ratio is defined as the ratio of capital expenditure and R&D spending excluding depreciation over a firm’s cash flow from operations. Overall, Eli Lilly has demonstrated strong performance across essential financial metrics. While its current valuation exceeds that of the broader market, this is a typical trend for companies with high growth. During the last three years, Eli Lilly's average annual sales growth has surpassed 20%, with an impressive 38% growth noted in the latest quarter. The company's average price-to-sales ratio during this period has been 14x. With obesity treatment projected as a $100B+ market by 2030, LLY stock forecast 2025 integrates aggressive adoption assumptions in U.S., EU, and APAC healthcare systems.